Thierry Buclin

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


504 publications

In press | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | ...
 
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Veuve F., Munting A., Cavassini M., Braun D., Günthard H.F., Duran Ramirez J.J. et al. Clinical pharmacology and therapeutics. Peer-reviewed.
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update.
Briki M., Murisier A., Guidi M., Seydoux C., Buclin T., Marzolini C., Girardin F.R., Thoma Y., Carrara S., Choong E. et al., 2024/02/03. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1236 p. 124039. Peer-reviewed.
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
Thoueille P., Cavassini M., Guidi M., Buclin T., Girardin F.R., Decosterd L.A., Marzolini C., 2024/02. Open forum infectious diseases, 11 (2) pp. ofae023. Peer-reviewed.
 
Pharmacovigilance. Sevrage et effet rebond: pas seulement avec les psychotropes [Pharmacovigilance. Withdrawal and rebound effects: not just with psychotropic drugs]
Marouf R., Chtioui H., Girardin F.R., Buclin T., Diezi L., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 96-101. Peer-reviewed.
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B. et al., 2024/01. The Lancet regional health. Europe, 36 p. 100793. Peer-reviewed.
Population pharmacokinetic analysis of doravirine in real-world people with HIV.
Thoueille P., Delarive L., Cavassini M., Buclin T., Decosterd L.A., Marzolini C., Girardin F.R., Guidi M., Swiss HIV Cohort Study, 2023/11/23. British journal of clinical pharmacology. Peer-reviewed.
Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
Tachet J., Versace F., Mercier T., Buclin T., Decosterd L.A., Choong E., Girardin F.R., 2023/11/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1230 p. 123917. Peer-reviewed.
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
Thoueille P., Delfraysse M., Andre P., Buclin T., Decosterd L.A., Fedeli C., Ustero P., Calmy A., Guidi M., Swiss HIV Cohort Study, 2023/09/27. BMC pharmacology & toxicology, 24 (1) p. 47. Peer-reviewed.
Supplementum 272: Abstracts of the Annual meeting of the Swiss Society of Gastroenterology, the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates
Juillerat Pascal, Tachet Jérémie, Mercier Thomas, Versace François, Guidi Monia, Buclin Thierry, Decosterd Laurent, Choong Eva, Girardin François, 2023/09/11., Annual meeting of the Swiss Society of Gastroenterology , the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver, the Swiss Society of Endoscopy Nurses and Associates pp. s3511 dans Swiss Medical Weekly, François. Peer-reviewed, SMW Supporting Association.
 
A Highly Sensitive HPLC-MS/MS MethodFor Multiplex Analysis Of Janus KinaseInhibitors In Plasma
Tachet J., Mercier T., André P., Guidi M., Buclin T., Decosterd L., Choong E., Girardin F., 2023/07. dans 19th World Congress of Basic and Clinical Pharmacology (WCP), Glasgow, July 2023.
Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.
Haefliger D., Marzolini C., Lamoth F., Pabst T., Buclin T., Livio F., 2023/07. British journal of clinical pharmacology, 89 (7) pp. 2304-2308. Peer-reviewed.
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Thoueille P., Alves Saldanha S., Desfontaine V., Kusejko K., Courlet P., Andre P., Cavassini M., Decosterd L.A., Buclin T., Guidi M. et al., 2023/06/01. The Journal of antimicrobial chemotherapy, 78 (6) pp. 1433-1443. Peer-reviewed.
 
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
Papadopoulou V., Degrauwe N., Decosterd L.A., Buclin T., Cairoli A., 2023/06. International journal of clinical pharmacology and therapeutics, 61 (6) pp. 270-272. Peer-reviewed.
An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.
Diezi L., Dao K., Jullien V., Roussel-Maupetit C., Burton I., André P., Bardinet C., Rothuizen L.E., Chtioui H., Manso-Silvan M.A. et al., 2023/02. Pharmacology research & perspectives, 11 (1) pp. e01032. Peer-reviewed.
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.
Overbeek J.K., Heine R.T., Verheul HMW, Chatelut E., Rudek M.A., Gurney H., Plummer R., Gilbert D.C., Buclin T., Burger D.M. et al., 2023/02. ESMO open, 8 (1) p. 100749. Peer-reviewed.
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.
Desfontaine V., Guinchard S., Marques S., Vocat A., Moulfi F., Versace F., Huser-Pitteloud J., Ivanyuk A., Bardinet C., Makarov V. et al., 2023/01/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1215 p. 123555. Peer-reviewed.
Estimating glomerular filtration rate from serum creatinine concentration in children with augmented renal clearance: all formulas are equivocal, but some are more equivocal than others.
André P., Chtioui H., Dao K., Rothuizen L.E., Di Paolo E.R., Diezi M., Crisinel P.A., Cachat F., Chehade H., Buclin T., 2023/01. Kidney international, 103 (1) pp. 225-226. Peer-reviewed.
From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure.
Goutelle S., Guidi M., Gotta V., Csajka C., Buclin T., Widmer N., 2023. Pharmaceutics, 15 (4) p. 1081. Peer-reviewed.
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
Briki M., André P., Thoma Y., Widmer N., Wagner A.D., Decosterd L.A., Buclin T., Guidi M., Carrara S., 2023. Pharmaceutics, 15 (4) p. 1283. Peer-reviewed.
Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy: A Comparative ENTIS Cohort Study.
Dao K., Shechtman S., Diav-Citrin O., George N., Richardson J.L., Rollason V., Pistelli A., Eleftheriou G., Berlin M., Ekobena P. et al., 2023. Journal of clinical psychopharmacology, 43 (1) pp. 12-19. Peer-reviewed.
Treatment-emergent adverse events and antiseizure medication actual drug load.
Prétat T., Aícua-Rapún I., André P., Lebon S., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2022/12. Epilepsy & behavior, 137 (Pt A) p. 108980. Peer-reviewed.
 
A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T., Desfontaine V., Cruchon S., Da Silva Pereira Clara J.A., Briki M., Mazza-Stalder J., Kajkus A., Burger R., Suttels V., Buclin T. et al., 2022/11/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1211 p. 123456. Peer-reviewed.
Inhibiteurs des Janus kinases : nouvelles perspectives pour la médecine de précision ? [Janus kinase inhibitors : new perspectives for precision medicine ?]
Tachet J., Dumusc A., Conrad C., Grandoni F., Chalandon Y., Ribi C., Buclin T., Girardin F., 2022/10/19. Revue medicale suisse, 18 (800) pp. 1979-1983. Peer-reviewed.
Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.
Goutelle S., Thoma Y., Buffet R., Philippe M., Buclin T., Guidi M., Csajka C., 2022/10/01. Pharmaceutics, 14 (10) p. 2107. Peer-reviewed.
Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
Vijiala S., André P., Buclin T., Decosterd L.A., Rossetti A.O., Novy J., 2022/09. European journal of neurology, 29 (9) pp. 2607-2611. Peer-reviewed.
Quantification of serotonin and eight of its metabolites in plasma of healthy volunteers by mass spectrometry.
Eugster P.J., Dunand M., Grund B., Ivanyuk A., Fogarasi Szabo N., Bardinet C., Abid K., Buclin T., Grouzmann E., Chtioui H., 2022/08/10. Clinica chimica acta; international journal of clinical chemistry, 535 pp. 19-26. Peer-reviewed.
 
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.
Girardin F., Manuel O., Marzolini C., Buclin T., 2022/08. Clinical microbiology and infection, 28 (8) pp. 1044-1046. Peer-reviewed.
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille P., Alves Saldanha S., Schaller F., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B., Furrer H. et al., 2022/07/29. Pharmaceutics, 14 (8) p. 1588. Peer-reviewed.
Development of an assay by liquid chromatography coupled to tandem mass spectrometry for thiopurines drugs in whole blood and application for their Therapeutic Drug Monitoring
Nguyen N., Da Silva Pereira Clara J. A., Mercier T., Desfontaines V., Ceppi F., Moradpour D., Chtioui H., André P., Buclin T., Decosterd L. A. et al., 2022/06/01. dans 6ème Congrès de printemps de la Société Suisse de Médecine Interne Générale du 1er juin 2022.
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
Courlet P., Buclin T., Biollaz J., Mazzoni I., Rabin O., Guidi M., 2022/04. CPT, 11 (4) pp. 469-481. Peer-reviewed.
Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.
Suttels V., André P., Thoma Y., Veuve F., Decosterd L., Guery B., Buclin T., 2022/04. JAC-antimicrobial resistance, 4 (2) pp. dlac043. Peer-reviewed.
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
Dao K., Fuchs A., André P., Giannoni E., Decosterd L.A., Marchetti O., Asner S.A., Pfister M., Widmer N., Buclin T. et al., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 457-465. Peer-reviewed.
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
Thoueille P., Choong E., Cavassini M., Buclin T., Decosterd L.A., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 290-302. Peer-reviewed.
Pharmacovigilance - Vaccins à ARNm contre le Covid-19 : le point sur les effets indésirables [Pharmacovigilance - mRNA COVID-19 vaccines : current state of knowledge on their adverse effects]
Favre V., Ekobena P., Chtioui H., Rothuizen L.E., Livio F., Genton B., Buclin T., 2022/02/02. Revue medicale suisse, 18 (767) pp. 190-197. Peer-reviewed.
 
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations.
Goutelle S., Woillard J.B., Buclin T., Bourguignon L., Yamada W., Csajka C., Neely M., Guidi M., 2022/02. Journal of clinical pharmacology, 62 (2) pp. 158-170. Peer-reviewed.
 
Parametric Approaches in Population Pharmacokinetics.
Guidi M., Csajka C., Buclin T., 2022/02. Journal of clinical pharmacology, 62 (2) pp. 125-141. Peer-reviewed.
 
Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!
André P., Diezi L., Dao K., Crisinel P.A., Rothuizen L.E., Chtioui H., Decosterd L.A., Diezi M., Asner S., Buclin T., 2022. Frontiers in pediatrics, 9 p. 768438. Peer-reviewed.
 
Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascendingdoses, phase-Ib trial in healthy volunteers
Chtioui H., Prod'Hom S., Desfontaine V., André P., Moulfi F., Bardinet C., Abo-Loha C., Tessieras J., Rothuizen L.E., Diezi L. et al., 2022. dans 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) - June 2022 Athens. European Journal of Clinical Pharmacology, 2022, 78: 1-163.
 
Safety, tolerability, pharmacokinetic profile and ex-vivo antitubercular acativity of macozinone formulated as spraydredi dispersion (SDD) versus native crystal powder (NCO?: single ascending doses, randomized, placebo-controlled, cross-ouver phase la trial in healthy volunteers
Rothuizen L.E., Ciullini L., Huser-Pitteloud J., Guidi M., Chtioui H., Ivanyuk A., André P., Bardinet C., Decosterd L.A., Spaggiari D. et al., 2022. dans SGAIM/SSMIG 6th Spring Congress Lausanne, June 2022. Primary and Hospital Care 2022: 22 (Suppl. 12), 173.
Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure.
Fluckiger P., Aícua-Rapún I., André P., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2022/01. Seizure, 94 pp. 66-69. Peer-reviewed.
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Burckhardt P., Faouzi M., Buclin T., Lamy O., The Swiss Denosumab Study Group, 2021/09. Journal of bone and mineral research, 36 (9) pp. 1717-1728. Peer-reviewed.
 
Seizure freedom and plasma levels of newer generation antiseizure medications.
Aícua-Rapún I., André P., Rossetti A.O., Décosterd L.A., Buclin T., Novy J., 2021/08. Acta neurologica Scandinavica, 144 (2) pp. 202-208. Peer-reviewed.
 
Tests thérapeutiques « N-of-1 » : vers une médecine personnalisée et fondée sur les preuves
Buclin T., Diezi L., 2021/08. Revue Prescrire, 41 (454) pp. 633-635.
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P., Guidi M., Alves Saldanha S., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C., 2021/07. European journal of clinical pharmacology, 77 (7) pp. 979-987. Peer-reviewed.
Médicaments, sexe et genre [Medicines, sex and gender]
Buclin T., Rothuizen L.E., Livio F., 2021/06/30. Revue medicale suisse, 17 (744-2) pp. 1262-1264. Peer-reviewed.
Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption.
Schneider A.G., André P., Scheier J., Schmidt M., Ziervogel H., Buclin T., Kindgen-Milles D., 2021/05/18. Scientific reports, 11 (1) p. 10493. Peer-reviewed.
 
Saliva therapeutic drug monitoring of the newer anti-epileptic drugs
Choong E., Novy J., Decosterd L., Buclin T., Rossetti A., Stampfli C., Vassalo P., Andre P., Aícua-Rapún I., 2021/04/15., Spring Meeting of the Swiss Society of Pharmacology and Toxicology dans SSPT 2021 Spring Meeting: Abstract Book. Peer-reviewed, Swiss Society of Pharmacology and Toxicology.
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A. et al., 2021/03. Clinical pharmacokinetics, 60 (3) pp. 379-390. Peer-reviewed.
 
Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.
Pauliat E., Onken M., Weber-Schoendorfer C., Rousson V., Addor M.C., Baud D., Théaudin M., Diav-Citrin O., Cottin J., Agusti A. et al., 2021/03. Multiple sclerosis, 27 (3) pp. 475-478. Peer-reviewed.
Liaisons dangereuses?
Buclin T., 2021/02/01..
Case Report: Colchicine Toxicokinetic Analysis in a Poisoned Child Requiring Extracorporeal Life Support.
Pérez Marín M., Prod'hom S., de Villiers S.F., Ferry T., Amiet V., Natterer J., Perez M.H., Buclin T., Chtioui H., Longchamp D., 2021. Frontiers in pediatrics, 9 p. 658347. Peer-reviewed.
No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent.
Biollaz J., Buclin T., Hildebrandt W., Décosterd L.A., Nussberger J., Swenson E.R., Bärtsch P., 2021/01/01. Journal of applied physiology, 130 (1) pp. 226-236. Peer-reviewed.
 
Pharmacokinetics of Anti-Infective Agents During CytoSorb Hemoadsorption: An Experimental Study
Antoine Schneider, Pascal André, Joerg Scheier, Monika Schmidt, Heiko Ziervogel, Thierry Buclin, Detlef Kindgen-Milles, 2020/12/30..
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
Decosterd L.A., Mercier T., Ternon B., Cruchon S., Guignard N., Lahrichi S., Pesse B., Rochat B., Burger R., Lamoth F. et al., 2020/11/10. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1157 p. 122160. Peer-reviewed.
Les étudiant·e·s en médecine mènent une recherche dans la communauté
Daeppen J.B., Gaume J., Bodenmann P., Buclin T., Fauvel A., Paroz S., Widmer D., Baumann M., 2020/10/21. Revue medicale suisse, 16 (711) p. 2007.
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P., Decosterd L.A., Alves Saldanha S., Cavassini M., Stader F., Stoeckle M., Buclin T., Marzolini C., Csajka C., Guidi M. et al., 2020/08. Clinical pharmacokinetics, 59 (8) pp. 1037-1048. Peer-reviewed.
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P., Alves Saldanha S., Cavassini M., Marzolini C., Choong E., Csajka C., Günthard H.F., André P., Buclin T., Desfontaine V. et al., 2020/06. Journal of mass spectrometry, 55 (6) pp. e4506. Peer-reviewed.
Traitements aggravant une infection par le COVID-19 : vraiment ? [Drugs that aggravate the course of COVID-19 : really ?]
Rothuizen L.E., Livio F., Buclin T., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 852-854. Peer-reviewed.
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K., Guidi M., André P., Giannoni E., Basterrechea S., Zhao W., Fuchs A., Pfister M., Buclin T., Csajka C., 2020/04. Pharmacological research, 154 p. 104278. Peer-reviewed.
 
Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Pérez Marín M., Decosterd L.A., Andre P., Buclin T., Mercier T., Murray K., Rizzi M., Meylan P., Jaton-Ogay K., Opota O. et al., 2020/02/28. Journal of the Pediatric Infectious Diseases Society, 9 (1) pp. 96-99. Peer-reviewed.
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.
Dao K., Thoueille P., Decosterd L.A., Mercier T., Guidi M., Bardinet C., Lebon S., Choong E., Castang A., Guittet C. et al., 2020/02. Pharmacology research & perspectives, 8 (1) pp. e00558. Peer-reviewed.
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy.
Barceló C., Guidi M., Thorball C.W., Hammer C., Chaouch A., Scherrer A.U., Hasse B., Cavassini M., Furrer H., Calmy A. et al., 2020/01. Open forum infectious diseases, 7 (1) pp. ofz464. Peer-reviewed.
 
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P., Stader F., Guidi M., Alves Saldanha S., Stoeckle M., Cavassini M., Battegay M., Buclin T., Decosterd L.A., Marzolini C. et al., 2020/01/01. AIDS, 34 (1) pp. 103-108. Peer-reviewed.
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
Buclin T., Thoma Y., Widmer N., André P., Guidi M., Csajka C., Decosterd L..A., 2020. Frontiers in Pharmacology, 11 p. 177. Peer-reviewed.
Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment.
Aícua-Rapún I., André P., Rossetti A.O., Ryvlin P., Hottinger A.F., Decosterd L.A., Buclin T., Novy J., 2020/01. Annals of neurology, 87 (1) pp. 22-29. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review.
Cardoso E., Guidi M., Blanchet B., Schneider M.P., Decosterd L.A., Buclin T., Csajka C., Widmer N., 2020. Therapeutic Drug Monitoring, 42 (1) pp. 33-44. Peer-reviewed.
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
Courlet P., Livio F., Guidi M., Cavassini M., Battegay M., Stoeckle M., Buclin T., Alves Saldanha S., Csajka C., Marzolini C. et al., 2019/12. Open forum infectious diseases, 6 (12) pp. ofz531. Peer-reviewed.
 
N-of-1 trials ou essais thérapeutiques individuels : un test probant pour diagnostiquer l’efficacité thérapeutique [N-of-1 trials or single-patient therapeutic tests: evidence-based tests to diagnose therapeutic efficacy]
Diezi L., Buclin T., 2019/11/06. Revue medicale suisse, 15 (670) pp. 2058-2061. Peer-reviewed.
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2690-2697. Peer-reviewed.
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
 
Automédication et douleur
Buclin Thierry, Diezi Léonore, Monney Aurélia, 2019/05. La Gazette médicale.
 
Clindamycin clearance during Cytosorb hemoadsorption: A case report and pharmacokinetic study.
Poli E.C., Simoni C., André P., Buclin T., Longchamp D., Perez M.H., Ferry T., Schneider A.G., 2019/05. The International journal of artificial organs, 42 (5) pp. 258-262. Peer-reviewed.
Pharmacovigilance, hémovigilance, vaccinovigilance, tératovigilance… : quelles retombées imprévues pour les patients, les intervenants de santé et les systèmes de soins ?
Buclin Thierry, Foley Rose-Anna, Livio Françoise, 2019/04/11. Anthropologie & Santé.
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Jermini M., Dubois J., Rodondi P.Y., Zaman K., Buclin T., Csajka C., Orcurto A., Rothuizen L.E., 2019/03/25. Scientific reports, 9 (1) p. 5078. Peer-reviewed.
 
Sub-picomolar quantification of PTH 1-34 in plasma by UHPLC-MS/MS after subcutaneous injection of teriparatide and identification of PTH 1-33, its degradation product.
Eugster P.J., Chtioui H., Herren A., Dunand M., Cappelle D., Bourquin J., Buclin T., Grouzmann E., 2019/03/20. Journal of pharmaceutical and biomedical analysis, 166 pp. 205-212. Peer-reviewed.
 
Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
Leuppi-Taegtmeyer A.B., Decosterd L., Osthoff M., Mueller N.J., Buclin T., Corti N., 2019/02. Antimicrobial agents and chemotherapy, 63 (2). Peer-reviewed.
Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.
Spaggiari D., Desfontaine V., Cruchon S., Guinchard S., Vocat A., Blattes E., Pitteloud J., Ciullini L., Bardinet C., Ivanyuk A. et al., 2019. PloS one, 14 (5) pp. e0217139. Peer-reviewed.
 
Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Blanc Mettral J., Faller N., Cruchon S., Sottas L., Buclin T., Schild L., Choong E., Nahimana A., Decosterd L.A., 2019. Drug metabolism letters, 13 (2) pp. 102-110. Peer-reviewed.
Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
Aicua-Rapun I., André P., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2019/01. Epilepsy research, 149 pp. 88-91. Peer-reviewed.
 
Precision dosing of imatinib: A model-based approach to optimize achievement of target exposure
Goutelle S., Widmer N., Buclin T., Csajka C., 2019., 23e Congrès de la Société Française de Pharmacologie et de Thérapeutique p. 35 dans Fundamental & Clinical Pharmacology. Peer-reviewed.
 
Therapeutic drug monitoring (TDM)
Pascal A., Widmer N., Buclin T., 2019. pp. 1-9 dans Swiss recommendations for adult cystic fibrosis care chap. 4.2.3, RMS Editions/Médecine et Hygiène.
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
 
Robustness analysis of personalised delivery rate computation for IV administered anesthetic
Simalatsar Alena, Guidi Monia, Roduit Pierre, Buclin Thierry, 2018/12. Smart Health, 9-10 pp. 101-114.
Levetiracetam circulating concentrations and response in status epilepticus.
Perrenoud M., André P., Buclin T., Decosterd L.A., Rossetti A.O., Novy J., 2018/11. Epilepsy & behavior, 88 pp. 61-65. Peer-reviewed.
 
Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.
Ivanyuk A., García Segarra N., Buclin T., Klein A., Jacquier D., Newman C.J., Bloetzer C., 2018/10. Neuromuscular disorders, 28 (10) pp. 865-867. Peer-reviewed.
 
Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring.
Tenaglia E., Ferretti A., Decosterd L.A., Werner D., Mercier T., Widmer N., Buclin T., Guiducci C., 2018/09/10. Journal of Pharmaceutical and Biomedical Analysis, 159 pp. 341-347. Peer-reviewed.
Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study.
Voumard R., Gardiol C., André P., Arensdorff L., Cochet C., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2018/09/01. The Journal of antimicrobial chemotherapy, 73 (9) pp. 2540-2545. Peer-reviewed.
 
Ethical approval for multicenter cohort studies on drug exposure during pregnancy: A survey among members of the European Network of Teratology Information Services (ENTIS).
Winterfeld U., Weber-Schöndorfer C., Schaefer C., von Elm E., Buclin T., 2018/09. Reproductive toxicology, 80 pp. 68-72. Peer-reviewed.
 
Sensitive quantification of the somatostatin analog AP102 in plasma by ultra-high pressure liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study in rats.
Eugster P.J., Boyle C.N., Prod'hom S., Tarasco E., Buclin T., Lutz T.A., Harris A.G., Grouzmann E., 2018/09. Drug testing and analysis, 10 (9) pp. 1448-1457. Peer-reviewed.
 
Antiepileptika in der Stillzeit : Wie beraten wir die Mütter? [Use of antiepileptic drugs during breastfeeding : What do we tell the mother?]
Crettenand M., Rossetti A.O., Buclin T., Winterfeld U., 2018/08. Der Nervenarzt, 89 (8) pp. 913-921. Peer-reviewed.
 
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
Cristina V., Mahachie J., Mauer M., Buclin T., Van Cutsem E., Roth A., Wagner A.D., 2018/07/01. JAMA oncology, 4 (7) pp. 1003-1006. Peer-reviewed.
 
LC-MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation.
Gallay J., Prod'hom S., Mercier T., Bardinet C., Spaggiari D., Pothin E., Buclin T., Genton B., Decosterd L.A., 2018/05/30. Journal of pharmaceutical and biomedical analysis, 154 pp. 263-277. Peer-reviewed.
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
 
Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.
Panchaud A., Rousson V., Vial T., Bernard N., Baud D., Amar E., De Santis M., Pistelli A., Dautriche A., Beau-Salinas F. et al., 2018/03. British journal of clinical pharmacology, 84 (3) pp. 568-578. Peer-reviewed.
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.
Conus P., Seidman L.J., Fournier M., Xin L., Cleusix M., Baumann P.S., Ferrari C., Cousins A., Alameda L., Gholam-Rezaee M. et al., 2018/02/15. Schizophrenia bulletin, 44 (2) pp. 317-327. Peer-reviewed.
 
Methods for Personalised Delivery Rate Computation for Propofol IV Administered Anesthetic
Simalatsar Alena, Guidi Monia, Roduit Pierre, Buclin Thierry, 2018. dans Automated Reasoning for System Biology and Medicine, Springer International Publishing.
 
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
Marzolini C., Decosterd L., Winterfeld U., Tissot F., Francini K., Buclin T., Livio F., 2017/12. British journal of clinical pharmacology, 83 (12) pp. 2835-2838. Peer-reviewed.
Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps.
Arensdorff L., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2613-2615. Peer-reviewed.
 
Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?
D'Anto J., Wnuk W., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2017/09. Epilepsy & behavior, 74 pp. 41-44. Peer-reviewed.
 
Renal Drug Transporters and Drug Interactions.
Ivanyuk A., Livio F., Biollaz J., Buclin T., 2017/08. Clinical pharmacokinetics, 56 (8) pp. 825-892. Peer-reviewed.
 
Guidance to develop individual dose recommendations for patients on chronic hemodialysis.
Gotta V., Dao K., Rodieux F., Buclin T., Livio F., Pfister M., 2017/07. Expert review of clinical pharmacology, 10 (7) pp. 737-752. Peer-reviewed.
Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT).
Voumard R., Van Neyghem N., Cochet C., Gardiol C., Decosterd L., Buclin T., de Valliere S., 2017/05/01. The Journal of antimicrobial chemotherapy, 72 (5) pp. 1462-1465. Peer-reviewed.
 
N-acetyl-cysteine in a double-blind randomized placebo-controlled trial: Towards biomarker guided treatment in early psychosis
Conus P., Fournier M., Xin L., Baumann P., Ferrari C., Cousins A., Alameda L., Golay P., Jenni R., Kashavan M.S. et al., 2017/04. pp. S806 dans European Psychiatry, Elsevier BV.
 
Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.
Dao K., Chtioui H., Lu Y., Peer C.J., Figg W.D., Pruijm M., Buclin T., Kissling S., 2017/04. American journal of kidney diseases, 69 (4) pp. 553-554. Peer-reviewed.
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
 
SA19. N-Acetyl-Cysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Do Kim, Seidman Larry J., Fournier Margot, Xin Lijing, Cleusix Martine, Baumann Philipp S., Ferrari Carina, Cousins Ann, Alameda Luis, Gholam-Rezaee Mehdi et al., 2017/03/01. pp. S119-S120 dans Schizophrenia Bulletin, Oxford University Press (OUP).
 
Adverse drug reactions as a cause of admission to intensive care unit: a 4-months prospective cohort study
Berthaut V., Renard D., Schaller M.D., Manzon C., Voirol P., Buclin T., Livio F., 2017., 17th International Society of Pharmacovigilance (ISoP) Annual Meeting, Liverpool p. 944 dans Drug Safety.
 
Direct oral anticoagulants: are they safer than vitamin K antagonists?
Baumberger M., Hugli O., Buclin T., Livio F., 2017., 17th International Society of Pharmacovigilance (ISoP) Annual Meeting, Liverpool pp. 943-944 dans Drug Safety.
 
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Dao K., Lu Y., Peer C.J., Figg W.D., Stadelmann R., Burnier M., Buclin T., Kissling S., 2017/01. Cancer chemotherapy and pharmacology, 79 (1) pp. 215-218. Peer-reviewed.
 
The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material.
Wahl P., Guidi M., Benninger E., Rönn K., Gautier E., Buclin T., Magnin J.L., Livio F., 2017. The Bone & Joint Journal, 99-B (11) pp. 1537-1544. Peer-reviewed.
 
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid.
Schaffer C., Buclin T., Jornayvaz F.R., Cazzaniga S., Borradori L., Gilliet M., Feldmeyer L., 2017. Dermatology, 233 (5) pp. 401-403. Peer-reviewed.
 
The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine
Decosterd L.A., Widmer N., André P., Aouri M., Buclin T., 2016/11. TrAC Trends in Analytical Chemistry, 84 pp. 5-13. Peer-reviewed.
 
Cascaded PID controller for anaesthesia delivery.
Simalatsar A., Guidi M., Buclin T., 2016/08. Conference proceedings, 2016 pp. 533-536. Peer-reviewed.
 
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Fuchs A., Rotzinger A., Cavassini M., Bugnon O., Buclin T., Schneider M.P., Csajka C., 2016/08. Therapeutic drug monitoring, 38 (4) pp. 506-515. Peer-reviewed.
Biases affecting injected doses of an experimental drug during clinical trials.
Perrottet N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2016/07/16. Trials, 17 (1) p. 321. Peer-reviewed.
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
 
Pregnancy outcome following maternal exposure to pregabalin may call for concern.
Winterfeld U., Merlob P., Baud D., Rousson V., Panchaud A., Rothuizen L.E., Bernard N., Vial T., Yates L.M., Pistelli A. et al., 2016/06/14. Neurology, 86 (24) pp. 2251-2257. Peer-reviewed.
 
Pharmacovigilance [Pharmacovigilance update]
Dao K., Chtioui H., Rothuizen L.E., Diezi L., Prod'hom S., Winterfeld U., Buclin T., Livio F., 2016/01/13. Revue medicale suisse, 12 (500) pp. 75-79.
Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants.
Fuchs A., Zimmermann L., Bickle Graz M., Cherpillod J., Tolsa J.F., Buclin T., Giannoni E., 2016. PloS one, 11 (7) pp. e0158806. Peer-reviewed.
 
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M., Barcelo C., Ternon B., Cavassini M., Anagnostopoulos A., Yerly S., Hugues H., Vernazza P., Günthard H.F., Buclin T. et al., 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 44 (1) pp. 151-161.
 
Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on Daphnia pulex.
Borgatta M., Waridel P., Decosterd L.A., Buclin T., Chèvre N., 2016. Science of the Total Environment, 545-546 pp. 21-29.
 
Paracétamol et ibuprofène en pédiatrie : Revue critique des indications, risques et autres points controversés
Dao Kim, Laubscher Bernard, Buclin Thierry, 2016. Paediatrica, 27 (2) pp. 30-34. Peer-reviewed.
 
Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication.
Kissling S., Fuchs A., Gobin N., Vogt B., Burnier M., Decosterd L.A., Buclin T., Livio F., 2015/11. International Journal of Antimicrobial Agents, 45 (3) pp. 325-327. Peer-reviewed.
 
Des doutes insuffisants pour changer nos pratiques
Winterfeld Ursula, Baud David, Panchaud Alice, Rothuizen Laura, Livio Françoise, Stoller Rudolf, Buclin Thierry, 2015/10. Bulletin des médecins suisses, 96 (41) pp. 1494-1495.
 
Suivi thérapeutique pharmacologique des inhibiteurs de protéines kinases
Buclin Thierry, Csajka Chantal, Guiducci Carlotta, Decosterd Laurent A, 2015/09. Innovations & Thérapeutiques en Oncologie, 1 (1) pp. 12-23.
 
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd L.A., Widmer N., Zaman K., Cardoso E., Buclin T., Csajka C., 2015/09. Biomarkers In Medicine, 9 (9) pp. 887-893. Peer-reviewed.
 
Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: Case report, pharmacokinetic modeling, and review of the literature.
Mani L.Y., Kissling S., Viceic D., Vogt B., Burnier M., Buclin T., Renard D., 2015/07. Hemodialysis International. International Symposium On Home Hemodialysis, 19 (2) pp. 333-343. Peer-reviewed.
 
Multiplex Mass Spectrometry Analysis of Latest-Generation Antiepileptic Drugs: A Clinically Useful Laboratory Tool for Improved Real-Time Patients' Care.
Decosterd LA, Mercier T, André P, Bertholet S, Rothuizen LE, Rossetti AO, Buclin T, 2015/06. Epileptologie, 32 (2) pp. 85-89.
 
Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.
Winterfeld U., Klinger G., Panchaud A., Stephens S., Arnon J., Malm H., Te Winkel B., Clementi M., Pistelli A., Maňáková E. et al., 2015/06. Journal of Clinical Psychopharmacology, 35 (3) pp. 250-259. Peer-reviewed.
 
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E., Buclin T., Guidi M., Quoix E., Gourieux B., Decosterd L.A., Gairard-Dory A.C., Ubeaud-Séquier G., Widmer N., 2015. Therapeutic Drug Monitoring, 37 (1) pp. 2-21. Peer-reviewed.
 
Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance.
Cappi G., Spiga F.M., Moncada Y., Ferretti A., Beyeler M., Bianchessi M., Decosterd L., Buclin T., Guiducci C., 2015. Analytical Chemistry, 87 (10) pp. 5278-5285.
 
Médicaments, grossesse et lactation.
Delaloye J.F., Panchaud A., Weisskopf E., Winterfeld U., Rothuizen L., Vial Y., Csajka C., Buclin T., Hohlfeld P., 2015/01., 4e éd. 252 p, Médecine et Hygiène.
 
Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: Relevance to the diagnosis of neuroblastoma.
Franscini L.C., Vazquez-Montes M., Buclin T., Perera R., Dunand M., Grouzmann E., Beck-Popovic M., 2015. Pediatric Blood and Cancer, 62 (4) pp. 587-593. Peer-reviewed.
 
Pharmacokinetics in hepatic impairment: Mind the protein binding.
Chtioui H., Buclin T., 2015. Journal of Hepatology, 63 (6) pp. 1539-1540. Peer-reviewed.
 
Pharmacovigilance [Pharmacovigilance update].
Fogarasi Szabo N., Diezi L., Delenclos L., Renard D., Chtioui H., Rothuizen L.E., Buclin T., Livio F., 2015/01. Revue Médicale Suisse, 11 (456-457) pp. 124-128.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
 
Setting-up a multi-center human research: Systematic observation during a Swiss clinical trial
Gotta V., Vallotton L., Buclin T., Widmer N., 2015. Bioethica Forum, 8 (1) pp. 25-28. Peer-reviewed.
 
The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study.
Borgatta M., Decosterd L.A., Waridel P., Buclin T., Chèvre N., 2015. Science of the Total Environment, 520 pp. 232-240.
 
Therapeutic Drug Monitoring of Antiepileptic Drugs in the 21st Century
André P., Novy J., Decosterd LA, Buclin T., Rothuizen LE, 2015/01/01. Epileptologie 32 pp. 78-84.
 
Dysménorrhée: patience, pilules ou bouillotte [Dysmenorrhea: patience, pills or hot-water bottle?].
Graz B., Savoy M., Buclin T., Bonvin E., 2014/11. Revue Médicale Suisse, 10 (452) pp. 2285-2288.
 
Nouveaux traitements de l'hépatite C: aspects pharmacologiques et potentiel d'interaction [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Chtioui H., Buclin T., Moradpour D., 2014/09. Revue Médicale Suisse, 10 (440) pp. 1600-4, 1606.
Antiepileptika bei Frauen im gebärfähigen Alter und in der Schwangerschaft : Vergleich der Fachinformationen in Deutschland und der Schweiz mit dem aktuellen Wissensstand [Antiepileptics in women of childbearing age and during pregnancy : Comparison of specialized information with the current state of knowledge in Germany and Switzerland].
Winterfeld U., Gotta V., Rothuizen L.E., Panchaud A., Rossetti A.O., Buclin T., 2014. Der Nervenarzt, 85 (6) pp. 738-746. Peer-reviewed.
 
Caractérisation du profil pharmacocinétique de la vancomycine chez des patients hospitalisés en médecine générale et chirurgie
Ribeiro J., Cerruti J., Widmer N., Livio F., Buclin T., Csajka C., Guidi M., 2014. dans 2e Congrès Suisse des Pharmaciens.
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L., Baerlocher G.M., Duchosal M.A. et al., 2014. Cancer Chemotherapy and Pharmacology, 74 (6) pp. 1307-1319. Peer-reviewed.
Dosing regimen of gentamicin in neonates: evaluation of current guidelines based on a large population pharmacokinetic analysis
Fuchs A., Guidi M., Giannoni E., Werner D., Widmer N., Buclin T., Csajka C., 2014. dans ESCIM 2014, European and Swiss Congress of Internal Medicin.
 
EzeCHiel: a story of individualized medicine validation - case of gentamicin dosing regimen optimisation in newborns
Fuchs A., Thoma Y., Sutter Y., Stadelmann J., Csajka C., Guidi M., Buclin T., Widmer N., 2014. dans Nano-Tera Annual Plenary Meeting 2014: Virtual Edition.
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
Is HLA-A*3101 screening cost-effective for preventing carbamazepine-induced severe toxidermia?
Decollogny Anne, Pinget Christophe, Rossetti Andrea, Buclin Thierry, Livio Françoise, 2014. dans European and Swiss Congress of Internal Medicine.
 
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V., Bouchet S., Widmer N., Schuld P., Decosterd L.A., Buclin T., Mahon F.X., Csajka C., Molimard M., 2014. Leukemia Research, 38 (7) pp. 764-772. Peer-reviewed.
 
Perampanel: a significant liver enzyme inducer in some patients?
Novy J., Rothuizen L.E., Buclin T., Rossetti A.O., 2014. European Neurology, 72 (3-4) pp. 213-216. Peer-reviewed.
 
Pharmacologie orthopédique
Livio F., Renard D., Senn L., Buclin T., 2014. pp. 35-70 dans Jolles-Haeberli B. (eds.) Manuel Pratique de Chirurgie Orthopédique chap. 2, Elsevier Masson.
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
 
Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.
Fuchs A., Guidi M., Giannoni E., Werner D., Buclin T., Widmer N., Csajka C., 2014. British Journal of Clinical Pharmacology, 78 (5) pp. 1090-1101. Peer-reviewed.
Tobramycin exposure from active calcium sulfate bone graft substitute.
Livio F., Wahl P., Csajka C., Gautier E., Buclin T., 2014. Bmc Pharmacology and Toxicology, 15 (1) p. 12. Peer-reviewed.
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Makarov V., Lechartier B., Zhang M., Neres J., van der Sar A.M., Raadsen S.A., Hartkoorn R.C., Ryabova O.B., Vocat A., Decosterd L.A. et al., 2014. Embo Molecular Medicine, 6 (3) pp. 372-383. Peer-reviewed.
Intravenous streptomycin dosing regimen in a patient undergoing hemodialysis: Plasma level monitoring and pharmacokinetic simulation
Chtioui H., Zbinden D., Manuel O., Entenza J., Decosterd L.A., Buclin T., 2013/08. pp. e106 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
A pain in the neck.
Puder J., Stadelmann R., Schoettker P., Buclin T., Grouzmann E., 2013. Clinical Chemistry, 59 (8) pp. 1280-1281.
 
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M., Calmy A., Hirschel B., Telenti A., Buclin T., Cavassini M., Rauch A., Decosterd L.A., 2013. Journal of Mass Spectrometry, 48 (5) pp. 616-625.
 
Authors' response to: Statins in pregnancy: safety and perspectives of therapeutic applications.
Winterfeld U., Allignol A., Panchaud A., Rothuizen L., Merlob P., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M. et al., 2013. BJOG, 120 (11) p. 1440.
 
Benchmarking therapeutic drug monitoring software: A review of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2013. Clinical Pharmacokinetics, 52 (1) pp. 9-22. Peer-reviewed.
 
Biases on the administered parenteral doses of an experimental drug during phase I clinical trials
Perrottet Ries N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2013. pp. e2-e3 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
 
EzeCHiel validation: Comparison of gentamicin drug concentration predictions to a reference method (NONMEM)
Fuchs A., Thoma Y., Csajka C., Buclin T., Widmer N., 2013. dans Nano-Tera Annual Plenary Meeting.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
Hemodialysis for cefepime intoxication: A case report
Mani L.Y., Kissling S., Burnier M., Buclin T., Renard D., 2013. pp. e24 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.
Dao K., Védy D., Lopez J., Staneczek O., Buclin T., Livio F., 2013. International journal of hematology, 97 (2) pp. 299-300.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
 
Pharmacokinetic interaction between methotrexate and chloral hydrate.
Dao K., Ivanyuk A., Buclin T., Beck-Popovic M., Diezi M., 2013. Pediatric Blood and Cancer, 60 (3) pp. 518-520.
Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders.
Wettach C., Thomann J., Lambrigger-Steiner C., Buclin T., Desmeules J., von Mandach U., 2013. Journal of Perinatal Medicine, 41 (3) pp. 301-307. Peer-reviewed.
Population pharmacokinetic study of gentamicin: A retrospective analysis in a large cohort of neonate patients
Fuchs A., Guidi M., Giannoni E., Buclin T., Widmer N., Csajka C., 2013. pp. Abstr. 2906 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Staehli Hodel E.M., Guidi M., Zanolari B., Mercier T., Duong S., Kabanywanyi A.M., Ariey F., Buclin T., Beck H.P., Decosterd L.A. et al., 2013. Malaria Journal, 12 p. 235. Peer-reviewed.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
Pregnancy outcome following maternal exposure to Mirtazapine: Preliminary results of a collaborative ENTIS study.
Winterfeld U., Buclin T., Klinger G., Panchaud A., Stephens S., Arnon J., Malm H., te Winkel B., Clementi M., Pistelli A. et al., 2013. pp. e1-e2 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
Winterfeld U., Allignol A., Panchaud A., Rothuizen L.E., Merlob P., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M. et al., 2013. BJOG, 120 (4) pp. 463-471. Peer-reviewed.
 
Prescription du monitoring pratique médicate: de l'empirisme eclairé aux stratégies rationnelles [Prescribing monitoring in clinical practice: from enlightened empiricism to rational strategies].
Buclin T., Herzig L., 2013. Revue Médicale Suisse, 9 (386) pp. 1037-1041.
 
Response to Diaz and de Leon "The Mathematics of Drug Dose Individualization Should be Built With Random Effects Linear Models".
Holford N.H., Buclin T., 2013. Therapeutic Drug Monitoring, 35 (6) pp. 873-874.
Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients
Gotta V., Buclin T., Widmer N., Csajka C., 2013. pp. Abstr. 2904 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
Strategies for the development of tdm for targeted anticancer agents
Buclin T., 2013. pp. e113-e114 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes
Gotta V., Buclin T., Csajka C., Widmer N., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 150-167. Peer-reviewed.
Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management.
Diezi M., Buclin T., Kuntzer T., 2013. Current Opinion in Neurology, 26 (5) pp. 481-488. Peer-reviewed.
Une attente encore trop longue. Du développement à l'utilisation la plus juste des nouveaux traitements.
Buclin T., 2013. Courrier du Médecin Vaudois 6 p. 7.
 
Agents anti-infectieux et fonction réna!e: vers des posologies sur mesure [Antimicrobial agents and renal elimination: towards individual dosage adjustment?].
Willi-Robatel C., Senn L., Livio F., Zanetti G., Marchetti O., Buclin T., 2012. Revue Médicale Suisse, 8 (338) pp. 894-900.
 
An agenda for UK clinical pharmacology: Monitoring drug therapy
Buclin T., Gotta V., Fuchs A., Widmer N., Aronson J., 2012. British Journal of Clinical Pharmacology, 73 (6) pp. 917-923.
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. pp. 113S-114S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. pp. Abstr. 2351 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. dans Nano-Tera Annual Plenary Meeting.
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A., Csajka C., Buclin T., Bolay S., Bille J., Calandra T., Marchetti O., 2012. Clinical Infectious Diseases, 55 (3) pp. 381-390.
 
Cytogenetic response to imatinib in chronic myeloid leukaemia patients: concentration dependency and associated influences under field-conditions
Gotta V., Bouchet S., Widmer N., Csajka C., Buclin T., Mahon F.-X., Molimard M., 2012. pp. 107S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
 
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Aouri M., Decosterd L.A., Buclin T., Hirschel B., Calmy A., Livio F., 2012. AIDS, 26 (6) pp. 776-778.
 
Etude d'inhalation contrôlée chez les fumeurs occasionnels et réguliers de cannabis: comparaison des profils cinétiques des cannabinoïdes et effets comportementaux (O11)
Giroud C., Fabritius M., Battistella G., Fornari E., Lauer E., Dao K., Mall J.-F., Appenzeller M., Annoni J.M., Favrat B. et al., 2012., Société Française de Toxicologie Analytique pp. S1-5/S1-6 dans 20e congrès de la Société Française de Toxicologie Analytique (SFTA) 19-21 septembre 2012, Chambéry, France, Annales de Toxicologie Analytique / Annals of Analytical Toxicology.
 
EzeCHiel: Drug concentration prediction and analysis software
Noverraz B., Stadelmann J., Sambuc L., Gotta V., Fuchs A., Widmer N., Buclin T., Thoma Y., 2012. dans Nano-Tera Annual Plenary Meeting.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient
Renard D., Gauthier T., Venetz J.-P., Buclin T., Kuntzer T., 2012. Clinical Kidney Journal, 5 (4) pp. 323-326. Peer-reviewed.
 
Monitoring drug therapy.
Buclin T., Gotta V., Fuchs A., Widmer N., Aronson J., 2012. British Journal of Clinical Pharmacology, 73 (6) pp. 917-923. Peer-reviewed.
 
Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma.
Grouzmann E., Matter M., Bilz S., Herren A., Triponez F., Henzen C., Kim K.S., Zulewski H., Buclin T., Brakch N. et al., 2012. Journal of Clinical Endocrinology and Metabolism, 97 (8) pp. 2773-2781.
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University